{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:39:46Z","timestamp":1791362386922,"version":"4.3.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.critrevonc.2026.105283","type":"journal-article","created":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T15:51:13Z","timestamp":1773589873000},"page":"105283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["From cold to hot: A 'Prime, Activate, Sustain' framework for precision remodeling of the tumor microenvironment in prostate cancer"],"prefix":"10.1016","volume":"222","author":[{"given":"Huimin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaisen","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2127-3126","authenticated-orcid":false,"given":"Meng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.critrevonc.2026.105283_bib1","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","article-title":"Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade","volume":"5","author":"Abida","year":"2019","journal-title":"JAMA Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105283_bib2","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S1470-2045(25)00209-8","article-title":"Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial","volume":"26","author":"Agarwal","year":"2025","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105283_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012454","article-title":"Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and\/or chemotherapy","volume":"13","author":"Andrews","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105283_bib4","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.18906","article-title":"Pathologist-read vs AI-driven assessment of tumor-infiltrating lymphocytes in melanoma","volume":"8","author":"Aung","year":"2025","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105283_bib5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","article-title":"Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer","volume":"35","author":"Beer","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105283_bib6","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J. Clinic."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105283_bib7","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-473080","article-title":"Connecting the dots: practical strategies for academic and community oncology synergy to advance multidisciplinary management in immunotherapy toxicity care","volume":"45","author":"Brazel","year":"2025","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105283_bib8","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.tem.2024.12.003","article-title":"Tumor-intrinsic regulators of the immune-cold microenvironment of prostate cancer","volume":"36","author":"Brea","year":"2025","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2026.105283_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102992","article-title":"Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: a systematic review and meta-analysis","volume":"151","author":"Buonerba","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105283_bib10","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae313","article-title":"A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancer","volume":"30","author":"Calvo","year":"2025","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105283_bib11","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105283_bib12","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.182766","article-title":"Targeting heterogeneous tumor microenvironments in pancreatic cancer mouse models of metastasis by TGF-\u03b2 depletion","volume":"9","author":"Chen","year":"2024","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105283_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105283_bib14","doi-asserted-by":"crossref","first-page":"11588","DOI":"10.3390\/ijms252111588","article-title":"Recent advances in artificial intelligence to improve immunotherapy and the use of digital twins to identify prognosis of patients with solid tumors","volume":"25","author":"D\u2019Orsi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105283_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007409","article-title":"Corticosteroid-resistant immune-related adverse events: a systematic review","volume":"12","author":"Daetwyler","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105283_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1515\/jbcpp-2024-0057","article-title":"Adiponcosis interplay: adipose tissue, microenvironment and prostate cancer","volume":"35","author":"Di Zazzo","year":"2024","journal-title":"J. Basic Clin. Physiol. Pharm."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105283_bib17","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1470-2045(25)00009-9","article-title":"Overall survival and quality of life with [177Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial","volume":"26","author":"Emmett","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105283_bib18","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.2147\/OTT.S145295","article-title":"Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma","volume":"10","author":"Gerendash","year":"2017","journal-title":"Onco Targets Ther."},{"issue":"7791","key":"10.1016\/j.critrevonc.2026.105283_bib19","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105283_bib20","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.cmet.2024.01.005","article-title":"Tumor-secreted FGF21 acts as an immune suppressor by rewiring cholesterol metabolism of CD8+ T cells","volume":"36","author":"Hu","year":"2024","journal-title":"Cell Metab."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105283_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009627","article-title":"Optimal timing of anti-PD-1 antibody combined with chemotherapy administration in patients with NSCLC","volume":"12","author":"Huo","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105283_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7403","article-title":"Multidisciplinary management of immunotherapy-related adverse events in solid tumors: an inter-institutional and telemedicine-based working team","volume":"13","author":"Iaculli","year":"2024","journal-title":"Cancer Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105283_bib23","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrurol.2018.9","article-title":"Clinical implications of PTEN loss in prostate cancer","volume":"15","author":"Jamaspishvili","year":"2018","journal-title":"Nat. Rev. Urol."},{"issue":"14","key":"10.1016\/j.critrevonc.2026.105283_bib24","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105283_bib25","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.coi.2018.03.004","article-title":"Chemokines and cancer: new immune checkpoints for cancer therapy","volume":"51","author":"Karin","year":"2018","journal-title":"Curr. Opin. Immunol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105283_bib26","doi-asserted-by":"crossref","DOI":"10.1200\/PO.21.00181","article-title":"Impact of circulating tumor DNA\u2013based detection of molecular residual disease on the conduct and design of clinical trials for solid tumors","author":"Kasi","year":"2022","journal-title":"JCO Precis. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105283_bib27","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s40824-023-00470-y","article-title":"Engineering TGF-\u03b2 inhibitor-encapsulated macrophage-inspired multi-functional nanoparticles for combination cancer immunotherapy","volume":"27","author":"Kim","year":"2023","journal-title":"Biomater. Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105283_bib28","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/s41571-024-00886-y","article-title":"Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials","volume":"21","author":"Kuo","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105283_bib29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13039-024-00680-6","article-title":"Loss of heterozygosity impacts MHC expression on the immune microenvironment in CDK12-mutated prostate cancer","volume":"17","author":"Lautert-Dutra","year":"2024","journal-title":"Mol. Cytogenet."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105283_bib30","doi-asserted-by":"crossref","first-page":"6261","DOI":"10.1038\/s41467-025-61560-0","article-title":"YY1 enhances HIF-1\u03b1 stability in tumor-associated macrophages to suppress anti-tumor immunity of prostate cancer in mice","volume":"16","author":"Li","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105283_bib31","first-page":"1","article-title":"Synergistic targeting strategies for prostate cancer","author":"Li","year":"2025","journal-title":"Nat. Rev. Urol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105283_bib32","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3724\/abbs.2023092","article-title":"Advances in landscape and related therapeutic targets of the prostate tumor microenvironment: therapeutic targets of the prostate tumor microenvironment","volume":"55","author":"Li","year":"2023","journal-title":"Acta Biochim. Et. Biophys. Sin."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105283_bib33","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ccell.2025.12.013","article-title":"Ubiquitination-directed cytosolic DNA degradation governs cGAS-STING-mediated immune response to DNA damage","volume":"44","author":"Li","year":"2026","journal-title":"Cancer Cell"},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105283_bib34","doi-asserted-by":"crossref","first-page":"6164","DOI":"10.1158\/1078-0432.CCR-21-2328","article-title":"Clinical impact of detecting low-frequency variants in cell-free DNA on treatment of castration-resistant prostate cancer","volume":"27","author":"Mizuno","year":"2021","journal-title":"Clin. Cancer Res"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105283_bib35","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1038\/s41591-024-03254-6","article-title":"ctDNA-based molecular residual disease and survival in resectable colorectal cancer","volume":"30","author":"Nakamura","year":"2024","journal-title":"Nat. Med."},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105283_bib36","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1158\/1078-0432.CCR-24-0400","article-title":"Evaluating immune checkpoint blockade in metastatic castration-resistant prostate cancers with deleterious CDK12 alterations in the phase 2 IMPACT trial","volume":"30","author":"Nguyen","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105283_bib37","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","article-title":"PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer","volume":"9","author":"Pantelidou","year":"2019","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105283_bib38","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN promotes resistance to T cell-mediated immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105283_bib39","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","article-title":"Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy","volume":"27","author":"Pitt","year":"2016","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105283_bib40","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105283_bib41","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.semcancer.2025.03.001","article-title":"The impact of the tumor microenvironment in the dual burden of obesity-cancer link","volume":"112","author":"Sagliocchi","year":"2025","journal-title":"Semin. Cancer Biol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105283_bib42","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105283_bib43","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/s41591-023-02284-w","article-title":"Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial","volume":"29","author":"Shenderov","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105283_bib44","article-title":"Immune-related adverse events in immunotherapy: challenges in diagnosis, monitoring, and management","volume":"14","author":"Siddiqui","year":"2025","journal-title":"Toxicol. Rep."},{"key":"10.1016\/j.critrevonc.2026.105283_bib45","article-title":"Sensitive quantification of cell-free tumor DNA for early detection of recurrence in colorectal cancer","volume":"12","author":"Stasik","year":"2021","journal-title":"Front Genet"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105283_bib46","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1186\/s12885-024-12940-0","article-title":"Sequential vs. concurrent systemic therapies in combination with FOLFOX-HAIC for locally advanced hepatocellular carcinoma: a single-center, real-world cohort study","volume":"24","author":"Sun","year":"2024","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105283_bib47","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","article-title":"Treatment of advanced prostate cancer","volume":"70","author":"Teo","year":"2019","journal-title":"Annu. Rev. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105283_bib48","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3390\/cells12050789","article-title":"Myeloid-derived suppressor cells (MDSC) in melanoma patients treated with anti-PD-1 immunotherapy","volume":"12","author":"Tomela","year":"2023","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105283_bib49","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-22-0228","article-title":"The androgen-thyroid hormone crosstalk in prostate cancer and the clinical implications","volume":"12","author":"Torabinejad","year":"2023","journal-title":"Eur. Thyroid J."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105283_bib50","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.annonc.2025.03.019","article-title":"Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune-checkpoint inhibitors: a systematic review and meta-analysis","volume":"36","author":"Valenza","year":"2025","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105283_bib51","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/s43018-022-00416-8","article-title":"Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer","volume":"3","author":"Vanguri","year":"2022","journal-title":"Nat. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105283_bib52","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","article-title":"Radiotherapy and immunotherapy: a beneficial liaison?","volume":"14","author":"Weichselbaum","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105283_bib53","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/j.cell.2018.04.034","article-title":"Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer","volume":"173","author":"Wu","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105283_bib54","article-title":"Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors","volume":"57","author":"Wu","year":"2025","journal-title":"Ann. Med."},{"issue":"52","key":"10.1016\/j.critrevonc.2026.105283_bib55","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2505658122","article-title":"A PSAT1 buff of YBX1 transcriptionally sustains HLA-E-mediated evasion of NK immunity","volume":"122","author":"Zhang","year":"2025","journal-title":"Proc. Natl. Acad. Sci."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T06:43:52Z","timestamp":1778481832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826001708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":55,"alternative-id":["S1040842826001708"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105283","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From cold to hot: A 'Prime, Activate, Sustain' framework for precision remodeling of the tumor microenvironment in prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105283","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105283"}}